Heart failure on ward

Patients admitted with acute decompensated HF (ADHF) have poor short- and long-term prognosis, after discharge ≈ 20% of patients are

readmitted within 30 days and up to 50% by 6 months. A reduction in HF readmissions simultaneously improves the

quality of care and reduces costs. To reduce HF readmission rates a comprehensive characterization of predictors of

readmission in patients with HF is imperative. Multivariable risk scores can predict risk for adverse events such as

readmission or mortality in patients admitted with ADHF. Next to natriuretic peptide levels, other biomarkers have emerged that allow prognostication of patients admitted with

ADHF. Recent studies have shown that combining multiple biomarkers in a multimarker panel, substantially improves

prediction of adverse events beyond current metrics. The primary objective of this study is to

perform an external validation of the ELAN-HF score in a cohort of patients admitted with ADHF at the Catharina

Hospital. A second primary objective is to serially measure a multimarker panel in this cohort and combine these

measurements with clinical data from multiple sources (e.g. prescribed medication, medical history, physiological

measurements etc.) to capture the heterogeneous nature of HF in a novel discharge risk score.

External validation of discharge risk score for patients admitted with acute decompensated heart failure (ADHF).

Determine added value of biomarkers in multimarker panel for discharge risk stratification of ADHF patients.

Determine added value of wrist-based PPG measurements after discharge in predicting readmission and/or mortality of ADHF patients.
Determine association between biomarkers and quality of life in patients with ADHF.

External validation of a Bayesian hemodynamics model in patients with ADHF.

Shortly after discharge (one to two weeks)

6 months after discharge

None